<< Back to Results
CALGB 40302 – Endocrine Therapy with or without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant with or without Lapatinib (GW572016) for Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer.
Clinical Trial Categories
- The Rosenfeld Cancer Center at 215-481-2402
- The Rosenfeld Cancer Center